KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Net Margin (2016 - 2025)

Historic Net Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to 82.06%.

  • Ionis Pharmaceuticals' Net Margin rose 229200.0% to 82.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 32.41%, marking a year-over-year increase of 123600.0%. This contributed to the annual value of 64.46% for FY2024, which is 178600.0% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Net Margin of 82.06% as of Q3 2025, which was up 229200.0% from 44.44% recorded in Q2 2025.
  • Ionis Pharmaceuticals' Net Margin's 5-year high stood at 50.85% during Q4 2021, with a 5-year trough of 119.52% in Q1 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' median Net Margin value was 61.96% (recorded in 2021), while the average stood at 54.74%.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Net Margin soared by 9206500bps in 2021, and later tumbled by -857000bps in 2022.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Net Margin stood at 50.85% in 2021, then tumbled by -169bps to 34.85% in 2022, then skyrocketed by 91bps to 3.08% in 2023, then tumbled by -1403bps to 46.35% in 2024, then plummeted by -77bps to 82.06% in 2025.
  • Its Net Margin stands at 82.06% for Q3 2025, versus 44.44% for Q2 2025 and 111.64% for Q1 2025.